Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Frequently asked questions
What sector does Athira Pharma, Inc (ATHA) operate in?
Athira Pharma, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Athira Pharma, Inc (ATHA) current stock price?
As of the latest data, Athira Pharma, Inc stock price is $7.66, with a previous close of $7.66.
What is Athira Pharma, Inc (ATHA) current market capitalization?
Athira Pharma, Inc market cap is approximately 30.21 million.
What is Athira Pharma, Inc (ATHA) Earnings Per Share (EPS)?
The trailing EPS is -$9.67, and the forward EPS is -$5.04.
Does Athira Pharma, Inc (ATHA) pay dividends?
No. Athira Pharma, Inc does not pay a dividend.
What is Athira Pharma, Inc (ATHA) beta (volatility) score?
Athira Pharma, Inc has a beta of 2.802, indicating very high volatility compared to the market.
